Safety of MP470 in Combination With Standard-of-Care Chemotherapy Regimens to Treat Solid Tumors

Exclusion Criteria

• •1. Any other active invasive malignancy except non-melanoma skin cancers or cervical carcinoma in situ.
• •2. History of significant cardiovascular disease such as uncontrolled or symptomatic arrhythmias, congestive heart failure and/or myocardial infarction.
• •3. Received any anticancer agent(s) within the past 3 weeks, including investigational agents, chemotherapy (6 weeks for nitrosoureas or mitomycin), immunotherapy, biologic or hormonal therapy other than LHRH agonists.
• •4. Received prior radiation therapy within the past 4 weeks.
• •5. Any serious, uncontrolled active infection that requires systemic treatment or known infection with HIV, HCV or HBV.
• •6. Patient requires treatment with immunosuppressive agents other than corticosteroids appropriate for the SOC chemotherapy regimen or those at stable doses for at least 2 weeks.